Melasma Treatment Advances: Non-Ablative Laser and Tranexamic Acid Combination Explained
Max Thorne posted on LinkedIn:
“Enhancing Melasma Treatment: Benefits of Non-Ablative Laser and Tranexamic Acid”
Understanding the Study on Melasma Treatment
This study looked at a new way to treat melasma, a skin condition that causes dark patches on the face. It combined two treatments: a non-ablative fractional laser (NAFL) and a topical medication called tranexamic acid (TXA). The goal was to see if this combination works better than using TXA alone.
What Worked?
The combination of NAFL and TXA showed better results in reducing melasma compared to TXA alone right after treatment.
Patients felt more satisfied with the results when using both treatments.
What Didn’t Work?
While there was improvement right after treatment, the benefits did not last long-term. Melasma returned in both groups during follow-ups.
After one and three months, there was no significant difference in results between the two treatment sides.
How Does This Help Patients and Clinics?
For patients, this study suggests that combining NAFL with TXA can provide quick improvements in melasma. However, it also highlights the need for ongoing treatment to maintain results. Clinics can use this information to offer more effective treatment options.
Real-World Opportunities
Clinics can start offering the combination treatment of NAFL and TXA for patients with melasma.
Doctors can educate patients about the potential for short-term improvement and the possibility of recurrence.
Measurable Outcomes to Track
Track changes in melasma severity using a standard scoring system.
Monitor patient satisfaction regularly after treatment.
Keep records of how long the results last before melasma returns.
AI Tools to Consider
Clinics might explore AI tools that can help analyze skin conditions or predict treatment outcomes based on patient data. These tools can assist in personalizing treatment plans.
Step-by-Step Plan for Clinics
Start by training staff on the new treatment combination of NAFL and TXA.
Begin with a small group of patients to monitor results and gather feedback.
Gradually expand the treatment offering based on initial success and patient satisfaction.
Regularly assess and adjust treatment plans based on patient outcomes and feedback.
For more details on the research, you can read the full study here.
Source
Title: Efficacy of Non-Ablative Fractional Laser Combined With Tranexamic Acid in Melasma Treatment: A Randomized Split-Face Trial
Authors: Amirhossein Rahimnia, Motahareh Hosnian, Amir houshang Ehsani, Pedram Nourmohammadpour, Zahra Shadlou, Mina Koohian Mohammadabadi, Ala Ehsani
Keep up with Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation